We are glad to inform you that Consorzio per Valutazioni Biologiche e Farmacologiche will provide its contribution in the fight against COVID-19 emergency. It was recently been entrusted by UPMC – University of Pittsburgh Medical Center with the two studies on COVID-19 which aim to test two vaccines in the form of a patch (protein subunit) and in intranasal spray (Adenovirus), both are phase I / II studies on healthy volunteers. In particular, the first study is a Phase I/ II Adaptive Clinical Trial to assess safety, tolerability and immunogenicity of PittCoVacc, a Microneedle Array Delivered SARS CoV- 2 Subunit Vaccine, in Healthy Adult Volunteers. The second is an open-label randomized Phase I/II clinical trial of Ad5.SARS-CoV-2-S1. CVBF will be involved in the whole study process, dealing with protocol finalisation, IB and IMPD preparation, submission, study management and monitoring, pharmacovigilance, data management and statistics.